ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Merck & Co. has bought a Yale University spinout called Modifi Biosciences for $30 million up front and the potential for more than $1.3 billion in milestone payments. Modifi is developing small molecules that can seek out cancer cells with DNA repair defects that make it difficult for the cells to develop resistance to treatment. Specifically, the start-up is targeting cancer cells lacking a protein called O6-methylguanine methyl transferase that’s critical to DNA repair. Modifi’s compounds have not yet been tested in humans.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter